Health
PharmAust continues to progress lead drug monepantel in treating canine and human cancers, COVID-19 – Small Caps
Six dogs have completed PharmAust’s (ASX: PAA) phase IIb trial evaluating its lead drug monepantel (MPL) in the most prevalent cancer in canines B-cell lymphoma….
Six dogs have completed PharmAusts (ASX: PAA) phase IIb trial evaluating its lead drug monepantel (MPL) in the most prevalent cancer in canines B-cell lymphoma.
During the March quarter, PharmAust revealed six dogs with stage four to five B-cell lymphoma had completed evaluation across five trial sites.
However, one dog was not in compliance with the trial process and was subsequently withdrawn.
PharmAust noted the remaining dogs side-effects were less than conventional anti-cancer drugs, with only…
-
Noosa News22 hours agoStudents say new facility would be better in rural areas of Queensland
-
General16 hours ago‘We are here for you’: PM to bring help to flood zones
-
General14 hours agoWe’ve all talked about potential economic consequences for Australia of Trump’s policies. Now they’re happening
-
Noosa News14 hours agoRates on hold; pressure builds for cuts in May